|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18,880.00 ARS | -1.97% |
|
-5.17% | +13.26% |
| 07-08 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
| 07-08 | Morgan Stanley Adjusts Price Target Amgen to $333 From $340, Maintains Equalweight Rating | MT |
| Market Cap | 196B 291,920B 172B 158B 146B 277B 18,717B 282B 1,892B 743B 9,221B 737B 721B 31,698B | P/E 2026 * |
23.8x | P/E 2027 * | 21.8x |
|---|---|---|---|---|---|
| Enterprise Value | 238B 354,541B 208B 192B 178B 337B 22,732B 343B 2,298B 902B 11,199B 895B 875B 38,498B | EV / Sales 2026 * |
6.31x | EV / Sales 2027 * | 6.02x |
| Free-Float |
99.78% | Yield 2026 * |
2.77% | Yield 2027 * | 2.93% |
Last Transcript: Amgen Inc.
| 1 day | -1.97% | ||
| 1 week | -5.17% | ||
| Current month | +0.05% | ||
| 1 month | +11.19% | ||
| 3 months | +9.32% | ||
| 6 months | +13.53% | ||
| Current year | +13.26% |
| 1 week | 18,800 |  | 19,750 |
| 1 month | 16,350 | | 20,350 |
| Current year | 15,920 | | 20,350 |
| 1 year | 12,320 | | 20,350 |
| 3 years | 3,875.33 | | 20,350 |
| 5 years | 1,280.17 | | 20,350 |
| 10 years | 273.67 | | 20,350 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
| Director of Finance/CFO | 62 | 2010-05-12 | |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 2019-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.97% | -5.17% | - | - | 196B | |
| -2.33% | -2.09% | +50.33% | +162.29% | 1,085B | |
| -0.82% | -2.30% | +62.97% | +61.11% | 624B | |
| -0.73% | -4.98% | +27.22% | +84.46% | 442B | |
| +0.33% | -1.17% | +27.98% | +26.90% | 332B | |
| -0.02% | -2.85% | +25.27% | +44.88% | 282B | |
| -3.89% | -11.22% | +20.78% | +26.07% | 277B | |
| +0.66% | -1.42% | -29.26% | -39.30% | 217B | |
| -3.72% | -1.10% | +13.35% | +71.53% | 167B | |
| -0.33% | -0.62% | -6.25% | -32.26% | 138B | |
| Average | -0.99% | -1.58% | +21.38% | +45.07% | 395.99B | |
| Weighted average by Cap. | -0.65% | -0.93% | +34.54% | +78.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.77B 56,182B 33.04B 30.47B 28.14B 53.4B 3,602B 54.3B 364B 143B 1,775B 142B 139B 6,101B | 38.7B 57,564B 33.85B 31.22B 28.84B 54.72B 3,691B 55.64B 373B 146B 1,818B 145B 142B 6,251B |
| Net income | 8.23B 12,244B 7.2B 6.64B 6.13B 11.64B 785B 11.83B 79.35B 31.16B 387B 30.91B 30.23B 1,330B | 8.86B 13,186B 7.75B 7.15B 6.61B 12.53B 845B 12.74B 85.46B 33.56B 417B 33.28B 32.56B 1,432B |
| Net Debt | 42.1B 62,621B 36.82B 33.96B 31.37B 59.52B 4,015B 60.52B 406B 159B 1,978B 158B 155B 6,800B | 36.55B 54,374B 31.97B 29.49B 27.24B 51.68B 3,486B 52.55B 352B 138B 1,717B 137B 134B 5,904B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-10 | ARS 18,880.00 | -1.97% | 180 |
| 26-07-08 | ARS 19,260.00 | -0.62% | 393 |
| 26-07-07 | ARS 19,380.00 | +1.04% | 342 |
| 26-07-06 | ARS 19,180.00 | -3.67% | 963 |
| 26-07-03 | ARS 19,910.00 | +1.69% | 272 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
- AMGN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
